Click Here to Register »

Executive Sponsor


Technology Sponsors


Associate Sponsor




Media Partners

BioPharm Insight
Bloomberg Brief
Can Biotech
Clinical Informatics News
Drug Delivery & Development
Health Economics
Larta Institute
Life Science Leader
Massachusetts Life Science Center
Medical News Today
Technology Networks


Tuesday, October 14, 2014

  • 8:00 am

  • Breakfast & Registration

  • 8:45 am

  • Chair’s Opening Remarks

    Chair’s Opening Remarks

    Barbara Lueckel, PhD
    Global Business Development Director, Roche

  • 9:00 am

  • Keynote Fireside Chat with Dr. Robert Langer, MIT

    Keynote Fireside Chat with Dr. Robert Langer, MIT

    Robert Langer, PhD
    David H. Koch Institute Professor, MIT

  • 9:50 am

  • Pharmaceutical Partnering Panel: Current Thinking on Scouting External Drug Delivery Technologies

    • Understanding the process and specific technology interests
    • Methods of sourcing external delivery technologies and DDS-enabled products
    • Key factors and criteria used during a scouting/evaluation process
    • Types of collaborations and deal terms
    • Examples of “high priority” DDS technologies of interest
    • Licensing platform technologies vs. drug-specific delivery system

    Richard Korsmeyer, PhD
    Senior Research Fellow, Head of External Technology & Collaborations, Pfizer

    Mary Gardner
    Director of Technology Assessment, Hospira

    Matthew Hilborn
    Strategic Technology & Business Development Specialist, GSK

    Keith Horspool, PhD
    VP, Pharmaceutical Development, Boehringer Ingelheim

  • 10:30 am

  • Networking Break & Partnering Meetings

  • 11:15 am

  • Non-invasive Delivery of Biotherapeutics Panel: Progress, Hurdles, and Commercialization Prospects

    Biologic drugs, such as insulin and antibodies, are currently delivered via injection, one of the least desirable routes of administration.  Despite improvements in delivery devices, there remains great interest in non-invasive delivery of these drugs.  Pulmonary, nasal, transdermal and oral delivery represent promising alternatives.  With biologics representing a $120 billion market, non-invasive biologic formulations address a significant unmet need for patients around the world.

    • Is oral delivery of macromolecules still considered the Holy Grail of drug delivery?
    • Technical challenges associated with non-injectable administration
    • Which non-invasive delivery approaches show the most promise and why?
    • What criteria are used to evaluate non-invasive delivery technologies?
    • What is the future of inhaled insulin (or biologics in general)?

    Julia Rashba-Step, PhD
    Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

    Tomas Landh, PhD
    Director, Strategy & Sourcing, Diabetes Research Unit, Novo Nordisk

    Andy Lewis, PhD
    Director Novel Formulation Technologies, CMC & Engineering Peptides, Ipsen

    Rob Saklatvala, PhD
    Director, Discovery Pharmaceutical Sciences, Merck

    Ping Yeh, PhD
    Executive Director, Drug Product Development, Process and Product Development, Amgen

  • 11:55 am

  • Drug Delivery Partnering Case Study featuring BIND Therapeutics, Inc. and AstraZeneca

  • 12:30 pm

  • Technology Spotlight: Progress on Developing 3M’s Hollow and Solid Microneedle Systems

    Mark Tomai, PhD
    Head of TLR and MTS Business Development, 3M Drug Delivery Systems

  • 12:45 pm

  • Lunch & Partnering Meetings

  • 2:00 pm

  • Drug Delivery Presentations in Two Tracks


    Track One – Drug Delivery Formulation Technologies

    Chaired by:
    Bruce Kerwin, PhD
    Scientific Director, Amgen

    Approximately 12-14 companies present formulation technologies that can enhance, enable, or facilitate delivery of a drug. Examples: nanoparticles, polymers/biodegradable materials, liposomes, tablets/capsules/liquids, conjugates, microparticles, lipids/emulsions, excipients, orally-disintegrating tablets/films, etc.


    Track Two – Drug Delivery Device Technologies

    Chaired by:
    Shawna Gvazdauskas
    Global Head of Device Strategy, External Opportunities & IP Liaison, Sanofi

    Approximately 12-14 companies present needle-free delivery devices, auto injectors, pen injectors, powder injection devices, microneedle systems, inhalation devices, nasal delivery devices, non-biodegradable implants or similar, transdermal patches, patch pumps and other wearable drug administration systems, etc.


    3:30 pm – 4:00 pm Break & Partnering Meetings

  • 5:30 pm

  • Networking Reception & Partnering Meetings


Wednesday, October 15, 2014

  • 8:00 am

  • Breakfast & Partnering Meetings

  • 8:30 am

  • Chair’s Opening Remarks

    Chair’s Opening Remarks

    Barbara Lueckel, PhD
    Global Business Development Director, Roche

  • 8:45 am

  • Keynote Presentation – TBA

  • 9:30 am

  • Delivery Device Platforms: A Strategy for Improving Development Cycle Times and Reducing Costs

    A platform drug delivery device can be attractive for pharma and biotech companies, potentially offering shorter development timelines and lower manufacturing costs. Companies are moving away from the bespoke device and exploring platform devices for pipeline and portfolio drugs, but this requires implementing a new device strategy which presents a new set of challenges. Therefore, this panel will discuss:

    • What steps should be taken to determine if a platform device strategy makes sense internally?
    • How do you implement and manage a platform device strategy
    • Pros and cons of licensing a platform device technology vs. developing internally
    • How have other industries done this successfully

    Paul Jansen
    Head Medical Device Development, Sanofi

    Eric Chanie
    Director, Head of Innovation Medical Devices, Merck Serono

    Kevin Deane
    Partner, Technology Group, PA Consulting Group

    Peter Krulevitch, PhD
    Engineering Director, Fellow, Primary Container and Drug Delivery Systems, Janssen R&D, Johnson & Johnson

    Atul Patel
    Director, Technical Development, Devices, BiogenIdec

    Anand Subramony, PhD
    VP, Drug Delivery & Device Development, MedImmune

  • 10:10 am

  • Networking Break & Partnering Meetings

  • 11:10 am

  • Fourth Annual Company Spotlights

  • 12:30 pm

  • Luncheon Roundtable Sessions & Partnering Meetings

    Luncheon Roundtable Sessions & Partnering Meetings
  • 1:45 pm

  • The Drug Delivery Investor Climate

    In this session, a panel of investors will discuss the current investment climate for drug delivery companies.  Key discussion points:

    • Overall market outlook for drug delivery investing
    • Trends in small company investing
    • Trends in drug delivery partnering
    • Sources of funding:  traditional and non-traditional
    • Technology areas generating “buzz” and attracting investors

    Brian Gallagher, Jr., PhD
    Partner, SR One, Ltd.

    David Hirsch, MD, PhD
    Managing Director, Longitude Capital

    Alex Zisson
    Partner, Thomas McNerney & Partners

  • 2:30 pm

  • DDS Technology Soapbox@PODD sponsored by Pfizer

    This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

    Julia Rashba-Step, PhD
    Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

    If you are interested in presenting on the Soapbox, please let us know at

  • 3:20 pm

  • Game-Changing Technologies for Targeted Delivery & Therapy for Chronic Brain Disorders

    Many diseases, such as Parkinson’s disease and epilepsy, are caused by the misfiring of neurons in the brain. The most promising treatments involve targeted delivery to the brain, but this remains a challenge, primarily due to the blood-brain barrier (BBB). This panel will explore cutting-edge targeting technologies that have the potential to change the way brain disorders are treated.

    PJ Anand
    Founder, President and CEO, Alcyone Sciences, Inc.

    Raghu Raghavan, PhD
    Partner and President, Therataxis, LLC

  • Conference Concludes